Cholinesterase Inhibitors in Mild Cognitive Impairment: A Systematic Review
Author Information
Author(s): Roberto Raschetti, Emiliano Albanese, Nicola Vanacore, Marina Maggini
Primary Institution: National Center for Epidemiology, Surveillance and Health Promotion, National Institute of Health, Rome, Italy
Hypothesis
Do cholinesterase inhibitors delay the conversion from mild cognitive impairment to Alzheimer's disease or dementia?
Conclusion
Cholinesterase inhibitors do not delay the onset of Alzheimer's disease or dementia in people with mild cognitive impairment.
Supporting Evidence
- No significant differences emerged in the probability of conversion from MCI to AD or dementia between treated and placebo groups.
- The rate of conversion ranged from 13% to 25% among treated patients and from 18% to 28% among placebo groups.
- Only one significant difference remained after adjusting for multiple comparisons, related to brain atrophy.
Takeaway
This study looked at whether certain drugs could help people with mild memory problems avoid getting worse, but it found that they didn't really help.
Methodology
The researchers conducted a systematic review of randomized controlled trials on cholinesterase inhibitors in patients with mild cognitive impairment.
Potential Biases
The trials were partially sponsored by pharmaceutical companies, which may introduce bias.
Limitations
The trials included were not homogeneous, and the definition of mild cognitive impairment varied across studies.
Participant Demographics
Participants were all over 50 years old, with a mix of genders; specific percentages were not consistently reported.
Statistical Information
Confidence Interval
0.64–1.12
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website